Arrowhead Research to Present at the 2011 MDB Capital Group Bright Lights Conference on May 10
Investors attending the conference are encouraged to schedule a one-on-one meeting at the conference with Arrowhead’s CEO Dr. Christopher Anzalone by contacting Brandi Floberg at email@example.com or 212-481-2050.
About Arrowhead Research Corporation
Arrowhead Research Corporation (NASDAQ: ARWR) is a nanomedicine company developing innovative therapeutic products at the interface of biology and nanoengineering to cure disease and improve human health. Arrowhead addresses its target markets through focused subsidiaries, which include: Calando Pharmaceuticals, a leader in delivering small RNAs for gene silencing; Ablaris Therapeutics, an anti-obesity therapeutics company; and Nanotope, a regenerative medicine company. For more information please visit http://www.arrowheadresearch.com.